Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Mucolytic enzyme (recombinant DNase)

Pulmozyme (dornase alfa)

An approved treatment for Cystic Fibrosis.

FDA Approved (1993)by Genentech, Inc., a member of the Roche Group
Preclinical
Phase 1
Phase 2
Phase 3
Approved
1993

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Dornase alfa wherever you encounter it, plus the key facts at a glance.

Generic name
Dornase alfa
Brand name
Pulmozyme
Drug class
Mucolytic enzyme (recombinant DNase)
Manufacturer
Genentech, Inc., a member of the Roche Group
How it's taken
Inhaled through a nebulizer, usually once a day

An enzyme breathed in through a nebulizer once a day that thins the thick mucus in the lungs of people with cystic fibrosis[1].

Pulmozyme is approved, alongside standard therapies, for children and adults with cystic fibrosis to improve lung function, and the FDA first approved it on December 30, 1993[1][2]. Its label has no boxed warning and lists no warnings or precautions[1].

Follow Pulmozyme by email

We'll email you when Pulmozyme's FDA label changes, when the FDA acts on it, and when new trials for Cystic Fibrosis open. Unsubscribe anytime.

You'll get, for Cystic Fibrosis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Dornase alfa fits

Pulmozyme (dornase alfa) is an inhaled enzyme approved since 1993 for children and adults with cystic fibrosis, used alongside standard therapies to improve lung function by thinning the DNA-rich mucus in the airways[1][2].

  • Pulmozyme does not change the faulty CFTR protein, which is what the CFTR modulators approved for cystic fibrosis, such as Trikafta for ages 2 and older and Alyftrek for ages 6 and older, are designed to do for people with a responsive CFTR variant[7][8].
  • Other inhaled medicines on the FDA-approved list for cystic fibrosis include the antibiotics Cayston (aztreonam) and TOBI (tobramycin) for people with Pseudomonas aeruginosa in the lungs, and Bronchitol (mannitol), an add-on for adults 18 and older who pass a tolerance test[9][10][11].
  • No Phase 3 trial comparing Pulmozyme with another FDA-approved cystic fibrosis medicine was found on ClinicalTrials.gov.
  • A small crossover study at Royal Brompton Hospital in London, where 20 of 38 children finished, found FEV1 rose 7.2% after 12 weeks of dornase alfa and 6.7% after 12 weeks of inhaled mannitol powder.
  • The authors concluded mannitol was at least as effective over 3 months, and cough and airway narrowing on mannitol led many children to drop out (Minasian and colleagues, Thorax, 2010)[6].
  • The SIMPLIFY trial found that among people 12 and older on Trikafta with well-preserved lung function, stopping dornase alfa for 6 weeks left lung function no different from continuing it, a short study that did not test longer periods or more advanced lung disease[4].
  • Anyone using Pulmozyme can ask their CF care team how it fits with their CFTR modulator, whether once or twice a day suits them, and which recommended nebulizer fits their age and breathing.

How Dornase alfa works

In cystic fibrosis, thick mucus stays in the airways, which lowers lung function and helps infections flare up, according to the Pulmozyme label[1]. Infected mucus holds very large amounts of loose DNA, released by white blood cells that gather to fight infection and then break down[1]. Dornase alfa is a lab-made copy of the human enzyme deoxyribonuclease I, with the same amino acid sequence as the natural enzyme, and it cuts that DNA apart[1].

In laboratory studies, it broke down the DNA in sputum from people with cystic fibrosis and made the sputum less thick and sticky[1]. Pulmozyme works on the mucus itself and does not change the faulty CFTR protein that causes cystic fibrosis. After a 2.5mg inhaled dose in 18 people with cystic fibrosis, the enzyme was measurable in sputum within 15 minutes at an average of 3µg/mL and fell to an average of 0.6µg/mL by 2 hours.

Blood levels did not rise significantly above normal even at doses up to 10mg 3 times a day, and no buildup was seen after 6 months of 2.5mg twice a day[1]. The protein is made in Chinese hamster ovary (CHO) cells[1].

Side effects and safety

What patients report
Label warnings
  • Allergy to the drug or to CHO cell products. Pulmozyme is not used in anyone with a known allergy to dornase alfa, to products made in Chinese hamster ovary cells or to any ingredient; the label lists no other warnings or precautions
  • Allergic reactions. no anaphylaxis has been reported; mild to moderate hives and mild rash have occurred and passed
  • Antibodies. an average of 2-4% of treated patients made antibodies to Pulmozyme, none had anaphylaxis, and what the antibodies mean is unknown
  • Pregnancy and breastfeeding. no adequate studies in pregnant women; animal studies at about 600 times the human dose showed no harm to the fetus, and it is not known whether Pulmozyme passes into human milk
Most common in trials
Voice changes (12-18% against 6-7% on placebo)Sore throat (32-40% against 28-33%)Rash (3-12% against 1-7%)Chest pain (18-25% against 16-23%)Laryngitis (3-4% against 1%)Conjunctivitis, or pink eye (1-5% against 0-2%)In more advanced lung disease, runny nose, fever and a single drop in FVC of 10% or more
What gets monitored
  • Each ampule squeezed before use to check for leaks, and not used if the solution is cloudy or discolored
  • Nebulizer cleaning, disinfection and part replacement as its maker's manual says
Report a suspected reaction to Genentech at 1-888-835-2555, or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
In context

The Pulmozyme label has no boxed warning and lists no warnings or precautions[1]. Pulmozyme is not used in people with a known allergy to dornase alfa, to products made in Chinese hamster ovary cells, or to any ingredient[1].

In the 6-month placebo-controlled trial in people whose FVC, a breathing test, was at least 40% of predicted, the side effects more common on Pulmozyme were voice changes (7% on placebo, 12% once a day, 16% twice a day), sore throat (33%, 36% and 40%), rash (7%, 10% and 12%), chest pain (16%, 18% and 21%), laryngitis (1%, 3% and 4%) and conjunctivitis (2%, 4% and 5%)[1].

Most of these were mild and short-lived and did not need a dose change, and 3% on Pulmozyme stopped for side effects, against 2% on placebo[1]. In the 12-week trial in people with more advanced lung disease (FVC below 40%), side effects more common on Pulmozyme included voice changes (18% against 6%), runny nose (30% against 24%), fever (32% against 28%), a single drop in FVC of 10% or more (22% against 17%), indigestion (3% against 0%) and serious shortness of breath (17% against 12%)[1].

In a 2-week study in 98 children aged 3 months to 10 years, side effects were similar to the controlled trials, and cough was reported more often in children under 5 (45%) than in older children (30%)[1]. Death rates in the controlled trials were similar on Pulmozyme and placebo, and the causes were consistent with cystic fibrosis getting worse[1].

No anaphylaxis has been reported, and about 2-4% of patients made antibodies to the drug with no known effect[1]. The label reports no clinically important drug interactions[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Dornase alfa

The usual dose is 2.5mg, the contents of 1 single-dose ampule, breathed in once a day through a recommended nebulizer, and the label says some patients may benefit from twice a day[1]. Short dose-ranging studies found doses above 2.5mg twice a day did not improve lung function further[1]. The label names the nebulizers to use.

The jet nebulizers are the Hudson T Up-draft II and Marquest Acorn II with a Pulmo-Aide compressor, the PARI LC Plus and PARI BABY with a PARI PRONEB compressor, and the Durable Sidestream with a MOBILAIRE or Porta-NEB compressor, or another legally marketed compressor of the same pressure and flow[1]. The vibrating mesh nebulizers are the eRapid Nebulizer System, the Innospire Go, the Pulmogine Vibrating Mesh Nebulizer and the AireHealth Nebulizer Intelligent Mesh Nebulizer[1].

The label says no data support other nebulizer systems[1]. The PARI BABY uses a face mask for children who cannot breathe in and out through the mouth for the whole treatment, and the eRapid is only for people who can use a mouthpiece[1]. Pulmozyme is not diluted or mixed with other drugs in the nebulizer, and an opened ampule is used in full or thrown away[1].

Each ampule holds 2.5mg in 2.5mL, and a carton holds 30 ampules in 5 foil pouches of 6[1]. Ampules are kept in the refrigerator at 36°F to 46°F in their foil pouch, and they are not used after more than a total of 60 hours at room temperature[1].

Availability and cost

No generic available

Only available as the brand-name product.

Why it costs what it costs

Pulmozyme is a protein drug made in living cells and sold only as the Genentech brand; as of November 19, 2026 no other dornase alfa product appears in the FDA's label or NDC listings[12]. The label gives no price. It is taken every day for years, so most of the cost runs through insurance, and Genentech's co-pay program, its patient foundation and independent charities named on pulmozyme.com help with what is left[13].

Help paying for Pulmozyme

With private insurance, the drugmaker's copay card can lower what you pay for Pulmozyme. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for Cystic Fibrosis were open on November 16, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Pulmozyme (Dornase alfa)
Genentech financial assistance for Pulmozyme
  • Copay help

    Pulmozyme Co-pay Program: eligible commercially insured patients pay as little as $30 for a 30-day supply, with out-of-pocket costs for Pulmozyme covered up to $10,000 per calendar year, but not other medicines, procedures or office visits. Not for Medicare, Medicaid, TRICARE or other government plans. The patient must be 18 or older or have a legally authorized adult, and live in the U.S. or a U.S. territory.

    For: private insurance · source
  • Free medicine program

    Genentech Patient Foundation: free Pulmozyme for uninsured people or insured people without coverage for it, with household income under $150,000. Insured people whose out-of-pocket maximum is over 7.5% of household income may also qualify. Requests need a Patient Consent Form and a Prescriber Foundation Form and are processed within 5 business days of both. Foundation line 888-941-3331, Monday to Friday, 6 AM to 5 PM Pacific.

    For: no insurance, underinsured · source

Good to know: Read on pulmozyme.com on November 19, 2026. The options line 866-422-2377 is open Monday to Friday, 6 AM to 5 PM Pacific. The page names the Cystic Fibrosis Foundation, The Assistance Fund and The HealthWell Foundation as independent charities. genentech-access.com's Pulmozyme page redirects to it.

Checked on the drugmaker's official pages on November 19, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Cystic Fibrosis

  • From a charity · The Assistance Fund
    Cystic Fibrosis fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and charity fund for Cystic Fibrosis →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Access and eligibility

Manufacturer
Genentech, Inc., a member of the Roche Group
Eligibility requirement

Approved, in addition to standard therapies, for children and adults with cystic fibrosis to improve lung function[1]. The label sets no lower age limit; use under 5 rests on results in older patients plus a 2-week safety study in children as young as 3 months[1]. The label says that in people whose FVC is at least 40% of predicted, daily use has also been shown to lower the risk of lung infections needing IV antibiotics[1]. Pulmozyme is not used in anyone with a known allergy to dornase alfa, to Chinese hamster ovary cell products or to any ingredient[1]. Clinical studies did not include enough people 65 or older to tell whether they respond differently[1].

Source: Pulmozyme financial assistance options

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Clinical trial results

The main trial randomized 968 people 5 and older with stable cystic fibrosis and FVC of at least 40% of predicted, all on standard therapies, to placebo (325), Pulmozyme 2.5mg once a day (322) or twice a day (321) for 6 months[1]. Lung infections needing IV antibiotics occurred in 43% on placebo, 34% on once a day and 33% on twice a day, a relative risk cut of 27% and 29%[1].

FEV1, the air breathed out in 1 second, rose 7.9% and 9.0% from baseline within 8 days and stayed about 5.8% and 5.6% above baseline over the trial, while placebo showed no significant change[1]. The label says the infection benefit may be smaller in people over 21, where twice a day dosing may be needed[1]. The trial was published in the New England Journal of Medicine in September 1994 by Fuchs and colleagues of the Pulmozyme Study Group[3].

A second 12-week trial in 320 people with FVC below 40% found FEV1 rose 9.4% on Pulmozyme against 2.1% on placebo and FVC 12.4% against 7.3%, but the risk of a lung infection needing IV antibiotics did not fall (54% against 55%)[1]. The label also says clinical trials indicated Pulmozyme can be started or continued during a flare of lung symptoms, and that its effect on exercise tolerance has not been established[1].

The dornase alfa part of the SIMPLIFY trial (NCT04378153), published in Lancet Respiratory Medicine in 2023, made 477 random assignments of people 12 and older on Trikafta with well-preserved lung function to stop or continue dornase alfa for 6 weeks, and the change in lung function did not differ between the groups[4][5].

Development history

Genentech developed dornase alfa as a lab-made copy of the human DNase I enzyme, and the FDA approved Pulmozyme on December 30, 1993 under BLA 103532[2]. The label updated in February 2024 reports changes to its dosing and nebulizer sections, and it now lists vibrating mesh nebulizers beside the jet nebulizers[1][2]. The label's pediatric section says use in children 5 to 17 rests on a randomized trial that included 303 patients in that age range, and use under 5 rests on those results plus safety data in 65 children aged 3 months to under 5[1].

As of November 19, 2026, Pulmozyme from Genentech is the only finished dornase alfa product in the FDA's drug label and NDC listings[12].

Ask anything about Dornase alfa
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Cystic Fibrosis trials

Other Cystic Fibrosis treatments

Common questions about Dornase alfa

▸What is Dornase alfa (Pulmozyme)?

An enzyme breathed in through a nebulizer once a day that thins the thick mucus in the lungs of people with cystic fibrosis[1]. Pulmozyme is approved, alongside standard therapies, for children and adults with cystic fibrosis to improve lung function, and the FDA first approved it on December 30, 1993[1][2]. Its label has no boxed warning and lists no warnings or precautions[1].

▸How does Dornase alfa work?

In cystic fibrosis, thick mucus stays in the airways, which lowers lung function and helps infections flare up, according to the Pulmozyme label[1]. Infected mucus holds very large amounts of loose DNA, released by white blood cells that gather to fight infection and then break down[1]. Dornase alfa is a lab-made copy of the human enzyme deoxyribonuclease I, with the same amino acid sequence as the natural enzyme, and it cuts that DNA apart[1]. In laboratory studies, it broke down the DNA in sputum from people with cystic fibrosis and made the sputum less thick and sticky[1]. Pulmozyme works on the mucus itself and does not change the faulty CFTR protein that causes cystic fibrosis. After a 2.5mg inhaled dose in 18 people with cystic fibrosis, the enzyme was measurable in sputum within 15 minutes at an average of 3µg/mL and fell to an average of 0.6µg/mL by 2 hours. Blood levels did not rise significantly above normal even at doses up to 10mg 3 times a day, and no buildup was seen after 6 months of 2.5mg twice a day[1]. The protein is made in Chinese hamster ovary (CHO) cells[1].

▸What are the side effects of Dornase alfa?

The Pulmozyme label has no boxed warning and lists no warnings or precautions[1]. Pulmozyme is not used in people with a known allergy to dornase alfa, to products made in Chinese hamster ovary cells, or to any ingredient[1]. In the 6-month placebo-controlled trial in people whose FVC, a breathing test, was at least 40% of predicted, the side effects more common on Pulmozyme were voice changes (7% on placebo, 12% once a day, 16% twice a day), sore throat (33%, 36% and 40%), rash (7%, 10% and 12%), chest pain (16%, 18% and 21%), laryngitis (1%, 3% and 4%) and conjunctivitis (2%, 4% and 5%)[1]. Most of these were mild and short-lived and did not need a dose change, and 3% on Pulmozyme stopped for side effects, against 2% on placebo[1]. In the 12-week trial in people with more advanced lung disease (FVC below 40%), side effects more common on Pulmozyme included voice changes (18% against 6%), runny nose (30% against 24%), fever (32% against 28%), a single drop in FVC of 10% or more (22% against 17%), indigestion (3% against 0%) and serious shortness of breath (17% against 12%)[1]. In a 2-week study in 98 children aged 3 months to 10 years, side effects were similar to the controlled trials, and cough was reported more often in children under 5 (45%) than in older children (30%)[1]. Death rates in the controlled trials were similar on Pulmozyme and placebo, and the causes were consistent with cystic fibrosis getting worse[1]. No anaphylaxis has been reported, and about 2-4% of patients made antibodies to the drug with no known effect[1]. The label reports no clinically important drug interactions[1].

▸How is Dornase alfa taken?

The usual dose is 2.5mg, the contents of 1 single-dose ampule, breathed in once a day through a recommended nebulizer, and the label says some patients may benefit from twice a day[1]. Short dose-ranging studies found doses above 2.5mg twice a day did not improve lung function further[1]. The label names the nebulizers to use. The jet nebulizers are the Hudson T Up-draft II and Marquest Acorn II with a Pulmo-Aide compressor, the PARI LC Plus and PARI BABY with a PARI PRONEB compressor, and the Durable Sidestream with a MOBILAIRE or Porta-NEB compressor, or another legally marketed compressor of the same pressure and flow[1]. The vibrating mesh nebulizers are the eRapid Nebulizer System, the Innospire Go, the Pulmogine Vibrating Mesh Nebulizer and the AireHealth Nebulizer Intelligent Mesh Nebulizer[1]. The label says no data support other nebulizer systems[1]. The PARI BABY uses a face mask for children who cannot breathe in and out through the mouth for the whole treatment, and the eRapid is only for people who can use a mouthpiece[1]. Pulmozyme is not diluted or mixed with other drugs in the nebulizer, and an opened ampule is used in full or thrown away[1]. Each ampule holds 2.5mg in 2.5mL, and a carton holds 30 ampules in 5 foil pouches of 6[1]. Ampules are kept in the refrigerator at 36°F to 46°F in their foil pouch, and they are not used after more than a total of 60 hours at room temperature[1].

▸Is Dornase alfa FDA approved?

Yes. The FDA approved Pulmozyme on December 30, 1993, and it is approved, alongside standard therapies, for children and adults with cystic fibrosis to improve lung function.

Infections: in people whose FVC is at least 40% of predicted, daily use has also been shown to lower the risk of lung infections needing IV antibiotics.

Age: the label sets no lower age limit, and its safety data include children as young as 3 months.

Generic: as of November 19, 2026, no other dornase alfa product appears in the FDA's label or NDC listings.

Source: Pulmozyme prescribing information

▸What nebulizer is used with Pulmozyme?

The Pulmozyme label lists specific jet and vibrating mesh nebulizers and says no data support other systems[1].

Jet nebulizers: Hudson T Up-draft II or Marquest Acorn II with a Pulmo-Aide compressor, PARI LC Plus or PARI BABY with a PARI PRONEB compressor, and Durable Sidestream with a MOBILAIRE or Porta-NEB compressor, or a legally marketed compressor of the same pressure and flow.

Vibrating mesh: eRapid Nebulizer System, Innospire Go, Pulmogine Vibrating Mesh Nebulizer and AireHealth Nebulizer Intelligent Mesh Nebulizer.

Face mask: the PARI BABY is for children who cannot breathe through the mouth for the whole treatment, and the eRapid is only for people who can use a mouthpiece.

Not mixed: Pulmozyme is not diluted or mixed with other drugs in the nebulizer.

Source: Pulmozyme prescribing information

▸What is the Pulmozyme dose?

The usual dose is 2.5mg, 1 single-dose ampule, breathed in once a day through a recommended nebulizer[1].

Twice a day: the label says some patients may benefit, and its main trial suggested people over 21 may need twice a day dosing for the infection benefit.

Higher doses: doses above 2.5mg twice a day did not improve lung function further in short studies.

Ampule: each holds 2.5mg in 2.5mL and is used in full once opened.

Source: Pulmozyme prescribing information

▸What are the side effects of Pulmozyme?

In the 6-month trial, voice changes, sore throat, rash, chest pain, laryngitis and pink eye were more common on Pulmozyme than on placebo, and most were mild and short-lived[1].

Voice changes: 12% once a day and 16% twice a day, against 7% on placebo.

Stopping: 3% on Pulmozyme stopped for side effects, against 2% on placebo.

Young children: cough was reported in 45% of children under 5 in a 2-week study, against 30% of those 5 to 10.

Allergy: no anaphylaxis has been reported, and Pulmozyme is not used with a known allergy to dornase alfa or Chinese hamster ovary cell products.

Source: Pulmozyme prescribing information

▸Does Pulmozyme need to be refrigerated?

Yes. Pulmozyme ampules are stored in the refrigerator at 36°F to 46°F, inside their foil pouch to protect them from light and heat[1].

Room temperature: ampules are not used after more than a total of 60 hours at 72°F to 82°F.

Travel: the label says to keep them refrigerated in the foil pouch.

Check first: an ampule that leaks, or a solution that is cloudy or discolored, is not used.

Source: Pulmozyme prescribing information

▸Is there a generic or biosimilar for Pulmozyme?

No other dornase alfa product appears in the FDA's drug label or NDC listings as of November 19, 2026, so Pulmozyme from Genentech is the only version found on the US market[12].

Why biosimilar: dornase alfa is a protein made in living cells, so a copy would be a biosimilar rather than a generic.

Source: openFDA NDC directory

▸Is there help paying for Pulmozyme?

Genentech offers a co-pay program for commercially insured patients and free drug through the Genentech Patient Foundation[13].

Co-pay: as little as $30 for a 30-day supply, with up to $10,000 per calendar year in help; not for Medicare, Medicaid, TRICARE or other government plans.

Free drug: for eligible people who are uninsured or whose plan does not cover Pulmozyme, with household income under $150,000.

Charities: pulmozyme.com names the Cystic Fibrosis Foundation, The Assistance Fund and The HealthWell Foundation as independent options.

Phone: 866-422-2377, or 888-941-3331 for the Foundation, Monday to Friday, 6 AM to 5 PM Pacific time.

Source: Pulmozyme financial assistance options

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Genentech, Inc. via DailyMed · 2025-12-17. PULMOZYME- dornase alfa solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8c78a7e-ff99-48f3-8952-643ec2ea0f86
  2. U.S. Food and Drug Administration · 1993-12-30. PULMOZYME approval history, BLA 103532. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103532
  3. N Engl J Med 1994;331(10):637-42 (PubMed) · 1994-09-08. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.. https://pubmed.ncbi.nlm.nih.gov/7503821/
  4. Lancet Respir Med 2023;11(4):329-340 (PubMed) · 2023-04. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. https://pubmed.ncbi.nlm.nih.gov/36343646/
  5. ClinicalTrials.gov. Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy. https://clinicaltrials.gov/study/NCT04378153
  6. Thorax 2010;65(1):51-6 (PubMed) · 2010-01. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial.. https://pubmed.ncbi.nlm.nih.gov/19996349/
  7. Vertex Pharmaceuticals Incorporated via DailyMed · 2026-06-22. TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f354423a-85c2-41c3-a9db-0f3aee135d8d
  8. Vertex Pharmaceuticals Incorporated via DailyMed · 2026-08-26. ALYFTREK (vanzacaftor, tezacaftor and deutivacaftor tablets). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e635909-c6fd-4f0d-ae77-cdff03653a20
  9. Gilead Sciences, Inc. via DailyMed · 2025-12-01. CAYSTON (aztreonam for inhalation solution). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67300ca3-8c53-4ce4-8e86-2c03be1f9b8a
  10. Viatris Specialty LLC via DailyMed · 2025-11-15. TOBI (tobramycin inhalation solution). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a3c3871-1d3a-44d6-8be3-526b30123ef7
  11. DailyMed · 2024-09-03. BRONCHITOL (mannitol inhalation powder). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2142460a-5afa-f3f3-e063-6394a90ab647
  12. U.S. Food and Drug Administration (openFDA) · 2026-11-19. NDC directory search for dornase alfa. https://api.fda.gov/drug/ndc.json?search=generic_name:%22dornase%22&limit=20
  13. Genentech. Financial Assistance Options | Pulmozyme® (dornase alfa). https://www.pulmozyme.com/patient/financial-support/assistance-options.html

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Pulmozyme by email

We'll email you when Pulmozyme's FDA label changes, when the FDA acts on it, and when new trials for Cystic Fibrosis open. Unsubscribe anytime.

You'll get, for Cystic Fibrosis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site